Latest news
Analyst Sees Larimar as Undervalued on Nomlabofusp’s Strong Efficacy and On‑Track BLA, Reiterates Buy Rating Ahead of 2027 FA Launch - TipRanksTipRanks · Thu, 06 Aug 2026 02:47:00 GMTRegulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp - TipRanksTipRanks · Wed, 05 Aug 2026 06:54:27 GMTLarimar Therapeutics (LRMR) Advances Nomlabofusp Submission Amid Mixed Financial Signals - GuruFocusGuruFocus · Tue, 04 Aug 2026 16:43:18 GMTLarimar reports Q2 results and nomlabofusp progress - TipRanksTipRanks · Tue, 04 Aug 2026 12:02:21 GMTLarimar Therapeutics Reports Positive Longer-Term Nomlabofusp Data and Progress Toward Rolling BLA Submission for Friedreich’s Ataxia - Quiver QuantitativeQuiver Quantitative · Tue, 04 Aug 2026 11:15:00 GMTLRMR: Rolling BLA submission for nomlabofusp underway; cash runway into Q3 2027, but more funding needed - TradingViewTradingView · Tue, 04 Aug 2026 11:12:57 GMTLRMR: Nomlabofusp advances toward approval with positive clinical data, FDA alignment, and strong cash runway - TradingViewTradingView · Tue, 04 Aug 2026 11:07:34 GMTLarimar Therapeutics advances nomlabofusp with positive data, rolling FDA submission, and Phase 3 start in 2026 - PluangPluang · Tue, 04 Aug 2026 07:00:00 GMT